Eiger BioPharmaceuticals Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, has appointed Christopher Kurtz as chief technical officer and Sarah Mathieson as senior vice president, Corporate Affairs.
 
“This is a pivotal year for Eiger, and I am pleased to welcome Chris and Sarah to the leadership team as our company continues to build momentum across our late-stage pipeline,” said David Cory, president and chief executive officer. “We are making great progress advancing our lead clinical programs in Hepatitis Delta Virus infection and expect topline data from the Phase 3 D-LIVR study by end of 2022. In addition, we recently announced positive topline data from the Phase 3 TOGETHER study of Peginterferon Lambda for COVID-19 and are actively working on an Emergency Use Authorization submission.”
 
“Expanding our leadership team with technical operations and corporate communications expertise is critical as we advance multiple, novel, first-in-class therapeutics to improve the lives of patients with serious diseases,” Cory added.

About Chris Kurtz

Kurtz brings nearly 30 years of technical operations and global biopharmaceutical manufacturing experience to Eiger. He has successfully established supply capabilities and navigated numerous products across late-stage development, scale-up, approval, and commercialization.
 
Previously, Kurtz served as executive vice president of Technical Operations at Cidara Therapeutics where he established and validated the supply chain for a novel antifungal agent. Prior to Cidara, he served as head of Commercial API Manufacturing at Gilead Sciences and before that was vice president of Drug Device Industrialization at AbbVie.
 
Kurtz holds a B.S. in Chemical Engineering from the University of Colorado and is a graduate of the Westinghouse S3G Nuclear Engineering Program. He was a member of the United States Navy, serving in the Submarine Force, where he graduated from the Naval Nuclear Propulsion School.

About Sarah Mathieson

Mathieson brings 25 years of biopharmaceutical corporate communications experience to Eiger. She most recently led Corporate Communications, Patient Advocacy and Engagement at Adamas Pharmaceuticals which was acquired by Supernus Pharmaceuticals.
 
Prior to Adamas, Mathieson served as chief executive officer for Research Autism, a non-profit organization focused on autism research and education in the UK. She previously held various leadership roles at GlaxoSmithKline Plc, including global head of Communications and Engagement where she oversaw the rebranding of GSK Consumer Healthcare, and global head of R&D Communications where she was responsible for science, product, and crisis communications as well as business development communications. Prior to GSK, Mathieson was head of Communications at Pfizer UK and was responsible for 20 products across all stages of development.
 
Mathieson holds a B.Sc. (Honors) in BioMedical Sciences from Portsmouth UK School of Pharmacy and Medical Sciences.